Abdominal wall hematoma is most commonly induced by a damage to the IEA, which is susceptible to iatrogenic injuries due to its superficial anatomical position (
3). IEA pseudoaneurysm is a rare presentation. Conservative treatment is effective in most cases; however, if the patient is symptomatic or hemodynamically unstable, appropriate management is necessary. Among various possible therapeutic options, transcatheter coil embolization is an effective treatment for pseudoaneurysm, with an overall success rate of 90 - 100% (
1,
6).
US-guided thrombin injection is widely accepted as a successful treatment for iatrogenic pseudoaneurysms, with a reported success rate of 75 to > 90% (
1,
3,
7). In our case, although total occlusion was immediately achieved by both coil embolization and thrombin injection, pseudoaneurysm recurred. There are several possible causes of unresponsiveness to treatment. According to a study by Shieman et al. (
7), an underlying occult vessel laceration or vessel infection can cause pseudoaneurysm recurrence after a percutaneous thrombin injection. Thrombomodulin, expressed by a damaged endothelium at the vessel laceration site, activates the anticoagulation pathway and leads to spontaneous thrombolysis, resulting in unresponsiveness to thrombin injection therapy (
8). This potentially explains our findings, since our patient had a recent history of abdominal surgery, which might have caused IEA laceration. Hematoma might have also acted as a nidus of infection, triggering vessel infection.
Importantly, our patient presented with ECF at the same time as the IEA pseudoaneurysm was first detected in the CT examination. ECF is a feared postsurgical complication with high morbidity and mortality rates (
5,
9). The majority of iatrogenic ECFs are due to anastomotic leakage or dehiscence, and spontaneous ECF is thought to be mainly induced by inflammatory processes (
4). Also, ECF itself can induce perilesional inflammation by succus and bacteria (
5). Although low-output ECF was observed in our case, it might have induced vascular infection, leading to pseudoaneurysm recurrence and increased rebleeding.
TAE using NBCA is an effective treatment for pseudoaneurysms (
2,
10). NBCA, as a fast-acting permanent embolic agent, enables simultaneous hemostasis of the bleeding focus and collateral vessels. Some characteristics of NBCA can explain the successful outcomes of our case. The operator could control the polymerization time by mixing NBCA with ethiodized oil at different ratios to avoid proximal occlusion in case of superselection difficulty due to anatomical tortuosity (
10). This approach also enables effective embolization in patients with a coil embolization history in whom microcoils cannot reach the neck or inflow/outflow vessels in the pseudoaneurysm (
2). Our patient had already undergone coil embolization; therefore, NBCA was an appropriate option for the recurred pseudoaneurysm. Also, NBCA is preferred for coil embolization when the patient has coagulopathy (similar to our case), because the therapeutic effect of NBCA does not depend on the coagulation process (
10).
Despite the several advantages mentioned above, we first used a microcoil rather than NBCA. The possible complications of NBCA, such as end-organ ischemia or non-target embolization, would have increased the patient burden considerably if the pseudoaneurysm was combined with an underlying ECF. Percutaneous thrombin injection was selected as not only an effective treatment with a low complication rate, but also a minimally invasive procedure with no radiation exposure. During the patient’s hospital stay, TPN and gradual shift to a fluid diet could successfully control the underlying ECF. We believe that this regimen contributed to the good outcomes of TAE using NBCA, without any associated complications.
Proper treatment should be decided when dealing with pseudoaneurysm, depending on not only the characteristics of the target lesion, such as the lesion size, location, and presence of outflow or collateral vessels (
10), but also the patient’s comorbidities and medical history, which can affect the rebleeding risk or recurrence. To the best of our knowledge, in the limited number of IEA pseudoaneurysms reported so far, there is no case of IEA pseudoaneurysm accompanied by postsurgical ECF, managed by endovascular and percutaneous treatments. Our case showed that an accompanying ECF could increase the unresponsiveness of IEA pseudoaneurysms to treatment by creating an inflammatory environment; therefore, repeated therapeutic trials with different embolic agents or methods might be needed to reach total occlusion.
In conclusion, our findings suggest that a coexisting ECF can affect the unresponsiveness of patients with IEA pseudoaneurysm to widely accepted treatments, such as coil embolization and thrombin injection by creating an inflammatory environment. In such cases, repeated therapeutic trials might be needed. TAE using NBCA can be an effective therapeutic option for patients with refractory IEA pseudoaneurysms combined with ECF.